UNSPSC 51161536: Doxofylline

This classification denotes a phosphodiesterase inhibitor with the molecular formula C11H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MPM23GMO7Z, chemically known as 7-(1,3-dioxolon-2-ylmethyl)-1,2,3,6-tetrahydro-1,3-dimethyl-2,6-purindion but generally known as doxofylline, which bears US NIH Compound Identifier 50942. European Medicines Agency schedules Doxofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06390MIG. The term DOXOFYLLINE is an International Non-Proprietary Name.

UNSPSC 51161536 Doxofylline (Commodity) addresses a narrow pharmaceutical input — a methylxanthine bronchodilator used primarily in respiratory treatment — that state and local governments procure through health departments, correctional facilities, and public health agencies for formulary inclusion and institutional dispensing. The code represents a specific active pharmaceutical ingredient rather than a broad service category, making it relevant only to jurisdictions maintaining inpatient or outpatient clinical operations with formulary management functions.

The source contains no recent state or local contract opportunities tagged to this code. Without posted RFPs, RFQs, IBFs, or ITBs naming doxofylline procurement, no geographic concentration, repeat issuing bodies, or representative solicitations can be identified. Activity under this Commodity code, if present, does not appear in the recent public notice record available to business development analysis.